63 related articles for article (PubMed ID: 25477091)
1. Drug combos validated in BRAF-mutant melanoma.
Cancer Discov; 2014 Dec; 4(12):1361-2. PubMed ID: 25477091
[TBL] [Abstract][Full Text] [Related]
2. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.
Kudchadkar R; Paraiso KH; Smalley KS
Cancer J; 2012; 18(2):124-31. PubMed ID: 22453012
[TBL] [Abstract][Full Text] [Related]
3. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
Chapman PB; Solit DB; Rosen N
Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
[TBL] [Abstract][Full Text] [Related]
4. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Girotti MR; Lopes F; Preece N; Niculescu-Duvaz D; Zambon A; Davies L; Whittaker S; Saturno G; Viros A; Pedersen M; Suijkerbuijk BM; Menard D; McLeary R; Johnson L; Fish L; Ejiama S; Sanchez-Laorden B; Hohloch J; Carragher N; Macleod K; Ashton G; Marusiak AA; Fusi A; Brognard J; Frame M; Lorigan P; Marais R; Springer C
Cancer Cell; 2015 Jan; 27(1):85-96. PubMed ID: 25500121
[TBL] [Abstract][Full Text] [Related]
5. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
Tembe V; Schramm SJ; Stark MS; Patrick E; Jayaswal V; Tang YH; Barbour A; Hayward NK; Thompson JF; Scolyer RA; Yang YH; Mann GJ
Pigment Cell Melanoma Res; 2015 May; 28(3):254-66. PubMed ID: 25490969
[TBL] [Abstract][Full Text] [Related]
7. Trafficking of T cells into tumors.
Slaney CY; Kershaw MH; Darcy PK
Cancer Res; 2014 Dec; 74(24):7168-74. PubMed ID: 25477332
[TBL] [Abstract][Full Text] [Related]
8. Melanoma BRAF fusions--response.
Hutchinson KE; Ross JS; Stephens PJ; Miller VA; Sosman JA; Pao W
Clin Cancer Res; 2014 Dec; 20(24):6632. PubMed ID: 25512636
[No Abstract] [Full Text] [Related]
9. The use of interferon in melanoma patients: a systematic review.
Di Trolio R; Simeone E; Di Lorenzo G; Buonerba C; Ascierto PA
Cytokine Growth Factor Rev; 2015 Apr; 26(2):203-12. PubMed ID: 25511547
[TBL] [Abstract][Full Text] [Related]
10. Skin cancer. Golden age of melanoma therapy.
Hutchinson L
Nat Rev Clin Oncol; 2015 Jan; 12(1):1. PubMed ID: 25511188
[No Abstract] [Full Text] [Related]
11. NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
Tucker H; Umeweni N; Robertson J; Adam J
Lancet Oncol; 2014 Dec; 15(13):1425-1426. PubMed ID: 25499274
[No Abstract] [Full Text] [Related]
12. Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.
Hoogstraat M; Gadellaa-van Hooijdonk CG; Ubink I; Besselink NJ; Pieterse M; Veldhuis W; van Stralen M; Meijer EF; Willems SM; Hadders MA; Kuilman T; Krijgsman O; Peeper DS; Koudijs MJ; Cuppen E; Voest EE; Lolkema MP
Pigment Cell Melanoma Res; 2015 May; 28(3):318-23. PubMed ID: 25515853
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib and cobimetinib in BRAF-mutated melanoma.
Rahman A
Lancet Oncol; 2014 Nov; 15(12):e535. PubMed ID: 25602110
[No Abstract] [Full Text] [Related]
14. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
[TBL] [Abstract][Full Text] [Related]
15. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
16. Systematic identification of signaling pathways with potential to confer anticancer drug resistance.
Martz CA; Ottina KA; Singleton KR; Jasper JS; Wardell SE; Peraza-Penton A; Anderson GR; Winter PS; Wang T; Alley HM; Kwong LN; Cooper ZA; Tetzlaff M; Chen PL; Rathmell JC; Flaherty KT; Wargo JA; McDonnell DP; Sabatini DM; Wood KC
Sci Signal; 2014 Dec; 7(357):ra121. PubMed ID: 25538079
[TBL] [Abstract][Full Text] [Related]
17. Melanoma BRAF fusions--letter.
Botton T; Yeh I; Bastian BC
Clin Cancer Res; 2014 Dec; 20(24):6631. PubMed ID: 25512635
[No Abstract] [Full Text] [Related]
18. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
Paulitschke V; Berger W; Paulitschke P; Hofstätter E; Knapp B; Dingelmaier-Hovorka R; Födinger D; Jäger W; Szekeres T; Meshcheryakova A; Bileck A; Pirker C; Pehamberger H; Gerner C; Kunstfeld R
Mol Cancer Ther; 2015 Mar; 14(3):757-68. PubMed ID: 25612618
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.
Perna D; Karreth FA; Rust AG; Perez-Mancera PA; Rashid M; Iorio F; Alifrangis C; Arends MJ; Bosenberg MW; Bollag G; Tuveson DA; Adams DJ
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):E536-45. PubMed ID: 25624498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]